���ϳԹ�

The defining properties of multipotent hematopoietic stem cells (HSCs) are their ability to differentiate into multiple lymphoid and myeloid lineages, as well as to self-renew to ensure that the HSC pool is not depleted over the lifespan of an individual. As HSCs proliferate, they progress through a series of lineage commitment steps, producing hematopoietic progenitor cells (HPCs) that are shorter-lived and more restricted in their differentiation potential.

The screening of novel compounds to predict potential toxicity to the hematopoietic system (i.e. hematotoxicity) is an important step in drug development. HemaTox™ assays can assess the toxicity of drugs on the growth and lineage-specific differentiation of human CD34+ hematopoietic stem and progenitor cells (HSPCs) into one of three specific progenitor cell lineages (erythroid, myeloid, or megakaryocyte).

Explore our scientific resources below to learn more about how to source, culture, and analyze HSPCs.